Posts With Tag HUTCHMED

Discover key insights from Hutchmed's Form 6-K filing, including upcoming financial results for 2024.

HUTCHMED (China) Limited's SEC Form 6-K reveals full NMPA approval for ORPATHYS, enhancing market prospects for treating advanced NSCLC. Filed January 14, 2025.

Explore HUTCHMED's latest Form 6-K, detailing a $608M joint venture divestment and NDA acceptance for ORPATHYS® in China. Key updates for investors and stakeholders.

Explore Hutchmed's SEC Form 6-K filed on December 31, 2024, announcing Cavendish as joint broker, highlighting strategic moves for enhanced market presence.

Explore HUTCHMED's December 2024 6-K report detailing SEC compliance and strategic blocklisting insights.